newsfilter
← Earnings
Earnings Releases·

Akari Therapeutics — Third Quarter 2026 Earnings Summary

  • Operating expenses decreased to $4.7 million in Q3 2026 from $7.4 million in the prior year period, driven by a $5.2 million impairment charge in 2025 related to the PHP-303 program; net loss narrowed to $4.8 million from $6.4 million year-over-year.
  • The Company repaid $0.7 million in convertible notes in full, leaving no debt outstanding, while raising $2.9 million from warrant exercises to bring the cash balance to $5.7 million as of September 30, 2026.
  • Preclinical data for lead candidate AKTX-101 demonstrated tumor growth inhibition in models refractory to current ADCs, and a collaboration with Whitehawk Therapeutics was announced to develop a novel dual payload construct.
  • Management plans to initiate a First-In-Human Phase 1 trial for AKTX-101 in mid-2027, contingent upon securing additional financing, while expanding the PH1 payload platform through internal development and strategic partnerships.
Company
AKARI THERAPEUTICS PLC
Sector
Healthcare
Industry
Biotechnology